Chinook Therapeutics, Inc.

Semaglutide Shows Promise in Reducing Albuminuria in Non-Diabetic Kidney Disease

7 months ago

• Semaglutide significantly reduced albuminuria in patients with chronic kidney disease (CKD) and obesity but without diabetes, according to the SMART trial. • The study demonstrated a 52.1% placebo-corrected reduction in urine albumin-to-creatinine ratio (UACR) at week 24 with semaglutide treatment. • Semaglutide also led to significant reductions in body weight and waist circumference, suggesting broader metabolic benefits in this patient population. • These findings suggest semaglutide's potential as a therapeutic option for non-diabetic CKD, warranting further investigation into long-term renal protection.